Inventor · disambiguated record
Brian Troy Frederick
Also filed as: FREDERICK BRIAN · FREDERICK BRIAN T · FREDERICK BRIAN TROY
27 granted patents·27 pending applications·368 citations·filing 2005–2025
97Inventor score
Files withPROTAGONIST THERAPEUTICS INC38JANSSEN BIOTECH INC7HOLMES CHRISTOPHER P4AFFYMAX INC3HEMBROUGH TODD1
Top patents by PatentIndex Score
54 records- 0198US10626146B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Apr 21, 2020·15 cites·22 claims
- 0297US10941183B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Mar 9, 2021·13 cites·20 claims
- 0397US10196424B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·26 cites·22 claims
- 0497US10059744B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·22 cites·31 claims
- 0597US10035824B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 31, 2018·24 cites·26 claims
- 0697US10023614B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 17, 2018·23 cites·21 claims
- 0797US9714270B2a4B7 integrin thioether peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·27 cites·22 claims
- 0897US9624268B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·40 cites·24 claims
- 0996US11472842B2Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·5 cites·11 claims
- 1096US10030061B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 24, 2018·29 cites·24 claims
- 1195US11807674B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·3 cites·4 claims
- 1295US11041000B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·13 cites·26 claims
- 1395US10729676B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·10 cites·18 claims
- 1495US10501515B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2019·18 cites·30 claims
- 1595US10442846B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·19 cites·19 claims
- 1695US9822157B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2014·Granted Nov 21, 2017·35 cites·9 claims
- 1794US11845808B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Dec 19, 2023·3 cites·30 claims
- 1894US10278957B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·16 cites·19 claims
- 1993US10787490B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·18 cites·18 claims
- 2088US11840581B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Dec 12, 2023·1 cites·17 claims
- 2188US2024199700A1Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2287US12269856B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
- 2386US11753443B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·3 cites·10 claims
- 2486US2024209026A1A4b7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2582US12018057B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Jun 25, 2024·1 cites·10 claims
- 2679US8106154B2Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromoleculesHOLMES CHRISTOPHER P·Filed 2008·Granted Jan 31, 2012·4 cites·4 claims
- 2779US2025340608A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2878US12234300B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 2976US11884748B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·21 claims
- 3072US2024150405A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 3172US2024383954A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 3272US2020239523A1NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3370US2024066131A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3470US2024018189A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3568US2023295259A1Conjugated Hepcidin MimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3667US12478617B2Lipidated peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2023·Granted Nov 25, 2025·0 cites·40 claims
- 3764US2025304624A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3864US2018100004A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3963US2024279281A1Peptide Inhibitors of Interleukin-23 ReceptorJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 4061US2022041658A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4158US2024352073A1Bicyclic peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 4257US2008108564A1Novel peptides that bind to the erythropoietin receptorAFFYMAX INC·Filed 2007·Application pending·0 cites
- 4357US2024409598A1Peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 4456US2020040037A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4554US2008090760A2Compositions and Methods for Inhibiting Cellular ProliferationHEMBROUGH TODD·Filed 2006·Application pending·0 cites
- 4653US2020017566A1Hepcidin and mini-hepcidin analogues and uses therofPROTAGONIST THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4752US2013012685A1Novel peptides that bind to the erythropoietin receptorAFFYMAX INC·Filed 2012·Application pending·0 cites
- 4851US2023129095A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4951US2019002503A1Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 5050US2011282029A1Novel peptides that bind to the erythropoietin receptorHOLMES CHRISTOPHER P·Filed 2010·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →